TLR9 and neoplasm: Currently, several preclinical and phase I/II studies also indicate that the administration of CpG oligodinucleotides (ODN), a TLR9 agonist, activates tumour-draining lymph node DCs and enhances the production of IFN-α/β cytokines, resulting in T cell activation.